Caelyx [CA] and paraplatin [PA] for patients with advanced ovarian cancer in late relapse

ABSTRACT

Introduction: 0varian cancer is the sixth most common malignancy [4.4% of cases] and also cause of death from cancer [4.5 %] in women worldwide. Epithelial tumors, arising from the swface of the ovary, account for approximately 90% of all ovarian malignancies. The vast majority [approximately 70%] of those patients with ovarian cancer present with advanced [stage III/IV] disease. Platinum-based chemotherapy, as a front-line therapy, is recommended for advanced-stage patients and those with high-risk early-stage disease. Liposomal doxorubicin has been evaluated in phase II trials with a good safety profile and efficacy